Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.

Saved in:
Bibliographic Details
Title: Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure.
Authors: Svoboda J; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Landsburg DJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Gerson J; University of Vermont Medical Center, Burlington., Nasta SD; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Barta SK; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Chong EA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Cook M; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Frey NV; Cell Therapy and Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Shea J; Cell Therapy and Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Cervini A; Cell Therapy and Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Marshall A; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Four M; Cell Therapy and Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Davis MM; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Jadlowsky JK; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Chew A; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Pequignot E; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Gonzalez V; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Noll JH; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Paruzzo L; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Cell Therapy and Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Rojas-Levine J; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Plesa G; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Scholler J; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Siegel DL; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Levine BL; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Porter DL; Cell Therapy and Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Ghassemi S; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Ruella M; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia.; Cell Therapy and Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Rech A; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Leskowitz RM; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Fraietta JA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.; Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia., Hwang WT; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia., Hexner E; Cell Therapy and Transplant Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia., June CH; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.; Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia.
Source: The New England journal of medicine [N Engl J Med] 2025 May 08; Vol. 392 (18), pp. 1824-1835.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1533-4406
DOI:10.1056/NEJMoa2408771